The Federal Trade Commission is weighing a potential antitrust lawsuit that could challenge Globus Medical's more than $3 billion proposed acquisition of NuVasive, Seeking Alpha reported July 20.
Wells Fargo said in a July 19 note that the acquisition is likely under FTC scrutiny, the report said. Reports from Capitol Forum also said the deal could give physicians fewer options for medical devices.
The deal spread widened from $2.87 to $3.31, according to Seeking Alpha. Shareholders from Globus Medical and NuVasive approved the deal in April.